206 related articles for article (PubMed ID: 23614655)
1. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Oberstein PE; Hershman DL; Khanna LG; Chabot JA; Insel BJ; Neugut AI
Cancer Invest; 2013 Jun; 31(5):316-22. PubMed ID: 23614655
[TBL] [Abstract][Full Text] [Related]
2. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
[TBL] [Abstract][Full Text] [Related]
3. Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Kourie HR; Gharios J; Kattan J
Future Oncol; 2017 Feb; 13(3):197-199. PubMed ID: 27624286
[No Abstract] [Full Text] [Related]
4. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP; Syrigos K; Aravantinos G; Polyzos A; Papakotoulas P; Fountzilas G; Potamianou A; Ziras N; Boukovinas J; Varthalitis J; Androulakis N; Kotsakis A; Samonis G; Georgoulias V
Br J Cancer; 2006 Sep; 95(5):587-92. PubMed ID: 16909140
[TBL] [Abstract][Full Text] [Related]
7. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Boeck S; Heinemann V
J Clin Oncol; 2008 Mar; 26(7):1178-9; author reply 1179. PubMed ID: 18309957
[No Abstract] [Full Text] [Related]
8. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
10. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
Ioka T; Katayama K; Tanaka S; Takakura R; Ashida R; Kobayashi N; Taniai H
Jpn J Clin Oncol; 2013 Feb; 43(2):139-45. PubMed ID: 23275642
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Hamm J; Dancey J; Eisenberg PD; Dagenais M; Fields A; Hagan K; Greenberg B; Colwell B; Zee B; Tu D; Ottaway J; Humphrey R; Seymour L;
J Clin Oncol; 2003 Sep; 21(17):3296-302. PubMed ID: 12947065
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Saadati H; Peccerillo J; Kaley K; Schilsky ML; Saif MW
JOP; 2009 Sep; 10(5):573-5. PubMed ID: 19734642
[No Abstract] [Full Text] [Related]
13. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Maisonneuve P; Lowenfels AB
JAMA; 2007 Jun; 297(23):2581; author reply 2582. PubMed ID: 17579223
[No Abstract] [Full Text] [Related]
14. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic pancreatic cancer.
Ko AH; Tempero MA
J Natl Compr Canc Netw; 2005 Sep; 3(5):627-36. PubMed ID: 16194454
[TBL] [Abstract][Full Text] [Related]
17. Unprecedented case of tumor lysis syndrome in a patient with metastatic pancreatic adenocarcinoma.
Ling W; Sachdeva P; Wong AS; Lee SC; Zee YK
Pancreas; 2012 May; 41(4):659-61. PubMed ID: 22504387
[No Abstract] [Full Text] [Related]
18. Gemcitabine in elderly patients with advanced pancreatic cancer.
Hentic O; Dreyer C; Rebours V; Zappa M; Lévy P; Raymond E; Ruszniewski P; Hammel P
World J Gastroenterol; 2011 Aug; 17(30):3497-502. PubMed ID: 21941416
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Saif MW
JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: a case treated with gemcitabine.
Takemura N; Fujii N; Tanaka T
J Dermatol; 2007 Sep; 34(9):662-4. PubMed ID: 17727372
[No Abstract] [Full Text] [Related]
[Next] [New Search]
